EUVIMEDEUVIMED entdecken
Crossref

Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab

Angeline A Truong iD, Savinnie Ho, Minna K I Apostolova, Rex H Lee iD, Xin Wu, Hyunseok Kang iD, Ivan H El-Sayed iD, Jonathan R George, Chase M Heaton iD, Ilya Likhterov, Mary Jue Xu, Matthew H Spitzer und 3 weitere

Head & Neck · 2026-12 · 48 (12) · 3329-3336

DOI: 10.1002/hed.70362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 18.06.2026. Verfasst von Angeline A Truong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lymphatic Metastasis, Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 28 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic implications of regional lymph node metastases at the initiation of immune checkpoint inhibitor (ICI) therapy in oral cavity squamous cell carcinoma (OCSCC) are not well defined. This study evaluated whether the presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with progression‐free or overall survival among patients with recurrent or metastatic (R/M) OCSCC.

Methods

A retrospective cohort study was conducted at a tertiary academic medical center including patients with R/M OCSCC who initiated pembrolizumab between May 2016 and May 2022. Patients receiving fewer than three cycles were excluded. The presence of metastatic lymph node(s) at ICI initiation was analyzed as a dichotomous variable. The primary outcome was 6‐month progression‐free survival (PFS), and the secondary outcome was 2‐year overall survival (OS). Disease progression was determined using RECIST‐based radiographic criteria. Cox proportional hazards models adjusted for age, PD‐L1 status, presence of distant metastases, and receipt of concurrent systemic therapy.

Results

Forty‐five patients met inclusion criteria; all received pembrolizumab for R/M disease. Twelve patients (27%) had metastatic cervical lymph nodes at ICI initiation. On univariate analysis, nodal metastasis was associated with poorer 6‐month PFS ( p = 0.024). After adjustment for age, PD‐L1 status, distant metastases, and concurrent systemic therapy, cervical nodal metastasis remained independently associated with inferior PFS (HR 5.12; 95% CI 1.30–20.2; p = 0.020).

Conclusions

Presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with reduced 6‐month progression‐free survival, suggesting regional disease burden may predict limited ICI benefit in R/M OCSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLymphatic MetastasisMouth NeoplasmsCarcinoma, Squamous CellAntineoplastic Agents, ImmunologicalSquamous Cell Carcinoma of Head and NeckHumansFemaleRetrospective StudiesMaleProgression-Free SurvivalMiddle AgedAgedLymph NodesPrognosisCohort Studies

Stichwörter der Autor:innen

head and neckimmunotherapymetastatic lymph nodepembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
  • Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • ENT Section, Department of Surgery, San Francisco VA Medical Center, San Francisco, California, USA.

ORCID-Profile: Angeline A Truong, Rex H Lee, Hyunseok Kang, Ivan H El-Sayed, Chase M Heaton, Patrick K Ha, Katherine C Wai

Förderung

  • NCI NIH HHS

Zitieren

APA

Truong, A. A., Ho, S., Apostolova, M. K. I., Lee, R. H., Wu, X., Kang, H., El-Sayed, I. H., George, J. R., Heaton, C. M., Likhterov, I., Xu, M. J., Spitzer, M. H., Ha, P. K., Algazi, A. P., & Wai, K. C. (2026). Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab. Head & Neck, 48(12), 3329-3336. https://doi.org/10.1002/hed.70362

Vancouver

Truong AA, Ho S, Apostolova MKI, Lee RH, Wu X, Kang H, et al. Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab. Head & Neck. 2026;48(12):3329-3336. doi:10.1002/hed.70362

BibTeX
@article{Truong2026,
  author = {Truong, Angeline A and Ho, Savinnie and Apostolova, Minna K I and Lee, Rex H and Wu, Xin and Kang, Hyunseok and El-Sayed, Ivan H and George, Jonathan R and Heaton, Chase M and Likhterov, Ilya and Xu, Mary Jue and Spitzer, Matthew H and Ha, Patrick K and Algazi, Alain P and Wai, Katherine C},
  title = {Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {12},
  pages = {3329--3336},
  doi = {10.1002/hed.70362}
}
Kostenlos starten →